| CAS NO: | 102767-28-2 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 50mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| Molecular Weight (MW) | 170.21 |
|---|---|
| Formula | C8H14N2O2 |
| CAS No. | 102767-28-2 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 34 mg/mL (199.8 mM) |
| Water: 34 mg/mL (199.8 mM) | |
| Ethanol: 34 mg/mL (199.8 mM) | |
| Solubility (In vivo) | Saline: 30 mg/mL |
| Synonyms | Levetiracetam, UCBL059, UCB L059, UCB-L059, SIB S1, SIBS1, SIB-S1, Keppra, Etiracetam, UCB6474, UCB-6474, UCB 6474, Chemical Name: (S)-2-(2-oxopyrrolidin-1-yl)butanamide InChi Key: HPHUVLMMVZITSG-LURJTMIESA-N InChi Code: InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1 SMILES Code: O=C(N)[C@H](CC)N1C(CCC1)=O |
| In Vitro | In vitro activity: Levetiracetam and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for Levetiracetam binding. Levetiracetam irreversibly inhibits the high-voltage-activated (HVA) calcium current by approximately 18% on the average in freshly isolated CA1 hippocampal neurons of rats. Levetiracetam selectively inhibits N-type Ca2+ channels of CA1 pyramidal hippocampal neurons. Levetiracetam reverses the inhibitory effect of DMCM on GABA-elicited currents in hippocampal neurons |
|---|---|
| In Vivo | Levetiracetam (17 mg/kg) produces a potent suppression of sound-induced clonic convulsions in mice, and this protective effect is significantly abolished by co-administration of the beta-carboline FG 7142. Levetiracetam exerts potent anticonvulsant activity against both focal and secondarily generalized seizures in fully amygdala-kindled rats, i.e. , a model of temporal lobe epilepsy. Levetiracetam (13 mg/kg, 27 mg/kg or 54 mg/kg, i.p.) dose-dependently suppresses the increase in seizure severity and duration induced by repeated amygdala stimulation. Levetiracetam has a relatively short half-life (about 2-3 hours) in rats. Levetiracetam (5.4 mg/kg to 96 mg/kg i.p.) dose-dependently inhibits both wild running and tonic-clonic convulsions in the audiogenic-seizure prone rat. Levetiracetam markedly suppresses spontaneous spike-and-wave discharge (SWD) but leaves the underlying EEG trace normal in the GAERS model of petit mal epilepsy. |
| Animal model | Mice |
| Formulation & Dosage | 5.4 mg/kg to 96 mg/kg i.p |
| References | Nature. 2005 May 26;435(7041):519-22; Br J Pharmacol. 2002 Jul;136(5):659-72. |
m.cnreagent.com